These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 27918372)

  • 1. The First 90 Days: Temporary Effect of Alemtuzumab on CMV Immune Reconstitution.
    Abate D
    Transplantation; 2017 Jul; 101(7):1522. PubMed ID: 27918372
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.
    Laurenti L; Piccioni P; Cattani P; Cingolani A; Efremov D; Chiusolo P; Tarnani M; Fadda G; Sica S; Leone G
    Haematologica; 2004 Oct; 89(10):1248-52. PubMed ID: 15477211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus Immunity After Alemtuzumab Induction in Desensitized Kidney Transplant Patients.
    Ge S; Karasyov A; Sinha A; Petrosyan A; Lovato D; Thomas DL; Vo A; Jordan SC; Toyoda M
    Transplantation; 2017 Jul; 101(7):1720-1726. PubMed ID: 27841845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opportunistic infections after alemtuzumab: New cases of norcardial infection and cytomegalovirus syndrome.
    Brownlee WJ; Chataway J
    Mult Scler; 2017 May; 23(6):876-877. PubMed ID: 28290753
    [No Abstract]   [Full Text] [Related]  

  • 5. Rapid reconstitution of CMV-specific T-cells after stem-cell transplantation.
    Widmann T; Sester U; Schmidt T; Gärtner BC; Schubert J; Pfreundschuh M; Sester M
    Eur J Haematol; 2018 Jul; 101(1):38-47. PubMed ID: 29652096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab.
    Lamba R; Carrum G; Myers GD; Bollard CM; Krance RA; Heslop HE; Brenner MK; Popat U
    Bone Marrow Transplant; 2005 Nov; 36(9):797-802. PubMed ID: 16151431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab.
    Vallejo C; Ríos E; de la Serna J; Jarque I; Ferrá C; Sánchez-Godoy P; Solano C; de la Cámara R; Rosell AI; Varela R; García MD; González-Barca E; López J; Pérez E; Ferrer S; Casado LF; Vázquez L; Villalón L; García-Marco JA
    Expert Rev Hematol; 2011 Feb; 4(1):9-16. PubMed ID: 21322774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin.
    Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Kim SH; Kim HJ; Cho SG; Eom KS; Lee JW; Min WS; Shin WS; Kim CC
    Transpl Infect Dis; 2009 Oct; 11(5):413-23. PubMed ID: 19708893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment.
    Barone S; Scannapieco S; Torti C; Filippelli E; Pisani V; Granata A; Console D; Demonte G; Tallarico T; Polidoro S; Quattrone A; Valentino P
    Mult Scler Relat Disord; 2018 Feb; 20():6-8. PubMed ID: 29272733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab.
    Cheung WW; Tse E; Leung AY; Yuen KY; Kwong YL
    Am J Hematol; 2007 Feb; 82(2):108-11. PubMed ID: 17013817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.
    O'Brien SM; Keating MJ; Mocarski ES
    Clin Lymphoma Myeloma; 2006 Sep; 7(2):125-30. PubMed ID: 17026823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
    Abate D; Cesaro S; Cofano S; Fiscon M; Saldan A; Varotto S; Mengoli C; Pillon M; Calore E; Biasolo MA; Cusinato R; Barzon L; Messina C; Carli M; Palù G
    Transplantation; 2012 Mar; 93(5):536-42. PubMed ID: 22314338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.
    Clerico M; De Mercanti S; Artusi CA; Durelli L; Naismith RT
    Mult Scler; 2017 May; 23(6):874-876. PubMed ID: 28290755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early reconstitution of effector memory CD4+ CMV-specific T cells protects against CMV reactivation following allogeneic SCT.
    Pourgheysari B; Piper KP; McLarnon A; Arrazi J; Bruton R; Clark F; Cook M; Mahendra P; Craddock C; Moss PA
    Bone Marrow Transplant; 2009 Jun; 43(11):853-61. PubMed ID: 19104497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring cytomegalovirus T-cell immunity in small bowel/multivisceral transplant recipients.
    Chiereghin A; Gabrielli L; Zanfi C; Petrisli E; Lauro A; Piccirilli G; Baccolini F; Dazzi A; Cescon M; Morelli MC; Pinna AD; Landini MP; Lazzarotto T
    Transplant Proc; 2010; 42(1):69-73. PubMed ID: 20172283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
    Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
    J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning.
    Kline J; Pollyea DA; Stock W; Artz A; Rich E; Godley L; Zimmerman T; Thompson K; Pursell K; Larson RA; van Besien K
    Bone Marrow Transplant; 2006 Feb; 37(3):307-10. PubMed ID: 16400339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coinfection with Human Cytomegalovirus Genetic Variants in Transplant Recipients and Its Impact on Antiviral T Cell Immune Reconstitution.
    Smith C; Brennan RM; Tey SK; Smyth MJ; Burrows SR; Miles JJ; Hill GR; Khanna R
    J Virol; 2016 Aug; 90(16):7497-507. PubMed ID: 27279616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation.
    Hill QA; Hill A; Collyns TA; Pearce RM; Cook G
    Bone Marrow Transplant; 2008 Apr; 41(8):749-51. PubMed ID: 18195685
    [No Abstract]   [Full Text] [Related]  

  • 20. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death.
    Schadde E; D'Alessandro AM; Knechtle SJ; Odorico J; Becker Y; Pirsch J; Sollinger H; Fernandez LA
    Transpl Int; 2008 Jul; 21(7):625-36. PubMed ID: 18397178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.